Normal view MARC view ISBD view

Evaluation of an unconventional treatment modality with mistletoe lectin to prevent recurrence of superficial bladder cancer: a randomized phase II trial. [electronic resource]

By:

Goebell, Peter J

Contributor(s):

Producer: 20020708Description: 72-5 p. digitalISSN:

0022-5347

Subject(s):

In: The Journal of urology vol. 168

Tags from this library: No tags from this library for this title. Log in to add tags.

Average rating: 0.0 (0 votes)

No physical items for this record

Publication Type: Clinical Trial; Comparative Study; Evaluation Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

There are no comments on this title.

to post a comment.

Back to results

1 "Forgiving" a missed daily dose.
by Macgregor, Thomas R
2 Case-control exploration of relationships between early rash or liver toxicity and plasma concentrations of nevirapine and primary metabolites.
by Hall, David B
3 Pharmacokinetic and safety evaluation of BILR 355, a second-generation nonnucleoside reverse transcriptase inhibitor, in healthy volunteers.
by Huang, Fenglei
4 Pharmacokinetic characterization of different dose combinations of coadministered tipranavir and ritonavir in healthy volunteers.
by MacGregor, Thomas R
5 Quantitation of five nevirapine oxidative metabolites in human plasma using liquid chromatography-tandem mass spectrometry.
by Rowland, Lois S
6 Assessment of nevirapine bioavailability from targeted sites in the human gastrointestinal tract.
by Macha, Sreeraj
7 Population pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with type 2 diabetes.
by Riggs, Matthew M
8 Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study.
by Kappelhoff, Bregt S
9 Pharmacokinetic assessment of nevirapine and metabolites in human immunodeficiency virus type 1-infected patients with hepatic fibrosis.
by Cammett, Anna Maria
10 In vitro-in vivo correlation for nevirapine extended release tablets.
by Macha, Sreeraj
11 Pharmacokinetic characterization of three doses of tipranavir boosted with ritonavir on highly active antiretroviral therapy in treatment-experienced HIV-1 patients.
by Goebel, Frank D
12 Coadministration with lopinavir and ritonavir decreases exposure to BILR 355, a nonnucleoside reverse transcriptase inhibitor, in healthy volunteers.
by Huang, Fenglei
13 Integration of absorption, distribution, metabolism, and elimination genotyping data into a population pharmacokinetic analysis of nevirapine.
by Lehr, Thorsten
14 Pharmacokinetics of BILR 355 after multiple oral doses coadministered with a low dose of ritonavir.
by Huang, Fenglei
15 Lack of a pharmacokinetic interaction between steady-state tipranavir/ritonavir and single-dose valacyclovir in healthy volunteers.
by Sabo, John P
16 Concomitant administration of BILR 355/r with emtricitabine/tenofovir disoproxil fumarate increases exposure to emtricitabine and tenofovir: a randomized, open-label, prospective study.
by Huang, Fenglei
17 Exposure-response modelling for empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in patients with type 2 diabetes.
by Riggs, Matthew M
18 Pharmacokinetics, safety, and efficacy of tipranavir boosted with ritonavir alone or in combination with other boosted protease inhibitors as part of optimized combination antiretroviral therapy in highly treatment-experienced patients (BI Study 1182.51).
by Walmsley, Sharon L
19 Pharmacokinetics of nevirapine: once-daily versus twice-daily dosing in the 2NN study.
by Kappelhoff, Bregt S
20 Steady-state disposition of the nonpeptidic protease inhibitor tipranavir when coadministered with ritonavir.
by Chen, Linzhi